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Introduction: DILI differs across geographical areas due to differen-
tial drug polices, prescription habits, drug consumption, and genetic 
factors. In this study, we have compared DILI cases included in the 
recently established Latin American DILI Network with those in 
the Spanish DILI Registry and the US Drug-Induced Liver Injury 
Network to identify differences in phenotypic presentations and 
causative agents.
Patients (or Materials) and Methods: Demographic, clinical 
parameters, and causative agents were compared between 98 Latin 
American, 851 Spanish, and 300 US DILI cases.
Results: The Latin American cases had a mean age of 54 years with 
a predominance of females (61%), whereas mean age and female 
proportion in the Spanish and US DILI cases were 54 years with 49% 
females and 48 years with 60% females, respectively. The most com-
mon type of liver damage in all 3 registries was hepatocellular injury. 
Jaundice was frequently seen in the registries, with 70%, 66%, and 
69% of the Latin American, Spanish, and US DILI cases, respectively. 
Hospitalization occurred in 51% of the Latin American DILI cases, 
with 57% and 60% of the Spanish and US cases requiring hospi-
talization. Liver-related death or liver transplantation occurred in 
5.1%, 3.6%, and 6.0% of the Latin American, Spanish, and US cases, 
respectively. The main causative agents in Latin America included 
nimesulide, diclofenac, nitrofurantoin, cyproterone acetate, and vari-
ous herbal remedies, whereas amoxicillin-clavulanate predominated 
in the other 2 registries, followed by ibuprofen in Spain and nitro-
furantoin in the United States.
Conclusion: The Latin American DILI cases demonstrate similar 
phenotypic characteristics as observed in registers outside Latin 
America with respect to type of injury and severity. Female sex 
predominates in the Latin America and US registries. With regard 
to causative agents, elevated representation of NSAIDs, hormonal 
treatments, and herbal remedies were seen in Latin America, whereas 
antibiotics were more common causes of DILI in Spain and the 
United States.
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Introduction: We report a case of cefepime intoxication with acute 
severe neurologic symptoms, which was treated by temporary hemo-
dialysis.
Patients (or Materials) and Methods: Cefepime 2 g BID for endo-
vascular prosthesis infection was prescribed to a frail, chronically ill 
88-year-old woman with a serum creatinine of 199 µmol/L and an 
estimated creatinine clearance of 13 mL/min (Cockroft formula). Two 
days later, she was transferred to a neurocritical care unit because 
of acute aphasia, myoclonic jerks, and delirium with a Glasgow 
coma scale score of 12/15. The following day, in the absence of 
other causes, cefepime intoxication was hypothesized, and cefepime 
was withdrawn after a total of 7 doses = 14 g. Over the next 24 
hours, two 3-hour hemodialysis (HD) sessions were performed under 
cefepime concentration monitoring.
Results: Cefepime plasma levels were measured by liquid chroma-
tography/mass spectrometry. There is no validated reference range, 
but a study (Chapuis T et al, Critical Care, 2010) found a 50% risk 
of neurotoxicity with residual levels > 15 mg/L. In our patient, levels 
were 83.3 mg/L 10 hours after last dose, 24.1 mg/L immediately after 
the first HD session, 13.4 mg/L immediately before the second HD 
session, and 2.5 mg/L immediately after the second HD session. The 
patient made a full clinical recovery over the next 48 hours. The 70% 
to 80% fall in plasmatic levels observed during each HD session is 
in accordance with literature data (Schmaldienst S et al, Eur J Clin 
Pharmacol, 2000, and Manyor LM et al, Pharmacotherapy, 2008). 
According to kinetic simulation, cefepime dropped at a concentration 
< 15 mg/L 15 hours earlier with HD than it would have without.
Conclusion: Neuropsychiatric adverse effects of beta-lactam antibi-
otics can be easily overlooked by clinicians. One should be especially 
cautious with their use in very old and frail patients in whom plasma 
creatinine poorly estimates renal function and cognitive impair-
ment is highly prevalent. Temporary hemodialysis effectively clears 
cefepime, but its role in hastening clinical recovery may be limited.
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Introduction: Hospitalization due to adverse drug events (ADE) is a 
well-known problem. According to the literature ADE are the reason 
for ~5% of hospitalizations. Recent pharmacoepidemiologic studies 
raised concern regarding the long-term safety of antipsychotic and 
antidepressant drugs. It was the aim to analyze the involvement of 
psychotropic drugs in ADE of patients presenting at an emergency 
department (ED).
Patients (or Materials) and Methods: In this prospective observa-
tional study, nontraumatic patients presenting at the ED of a tertiary 
care university teaching hospital were evaluated in 3 study phases by 
intensive chart review by an interdisciplinary expert panel to detect 
and classify all ADE.
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Results: A total of 2262 patients (62.1 [20.2] years (range, 17–102), 
1172 female) were evaluated in the study. Of these, 426 (18.8%) took 
psychotropic drugs at home. Comparing patients taking psychotropic 
drugs with patients not taking these drugs, they were significantly 
older (72.7 vs 59.7 years), took significantly more drugs at home 
(8.1 vs 3.6), and stayed significantly longer at the hospital (7.4 vs 5.3 
days) (all, P < 0.0001). In 134 (31.5%) patients taking psychotropic 
drugs, we identified 162 ADE (106 adverse drug reactions including 
QTc-prolongation, 56 associated with at least 1 medication error) as 
well as 98 medication errors without or with unknown clinical conse-
quences. In 80 patients, 1 or more ADE related to psychotropic drugs 
was a major contributing factor to hospitalization. Most frequently, 
patients suffered from the following symptoms: syncope (n = 33), 
somnolence (n = 12), seizures (n = 10), and anticholinergic effects 
(n = 8). In 49 (59.8%) of the 82 ADE associated with hospitalization, 
a drug–drug interaction was involved. At least 1 medication error 
(eg, ignored contraindication or missing indication) was involved 
in 31 (37.8%) of the ADE associated with hospitalization, which 
were, therefore, judged to be preventable. Based on the data avail-
able for 72 (87.8%) of the patients hospitalized because of ADE, the 
average treatment costs of ADE-related to psychotropic drugs was 
€ 2556 (2148).
Conclusion: Nearly one third of all patients taking psychotropic 
drugs suffered from a psychotropic drug-related ADE and nearly 
one fifth were hospitalized in relation to the ADE. That is, ADE due 
to psychotropic drugs are common, costly, and often preventable. 
Strategies have to be found to ensure the safe use of psychotropic 
drugs, especially for the elderly people with polypharmacy.
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Introduction: Prediction of serious DILI at early stages of drug devel-
opment is a major concern. A broad “Hy’s Law” definition as ALT 
> 3 × ULN and total bilirubin (TBL) > 2 × ULN has been used to 
predict a worst DILI outcome. We aimed to examine the best way to 
define Hy’s law by analyzing whether the R value provides a better 
way of identifying hepatocellular (HC) versus cholestatic (Chol) con-
tribution to injury at different time points, and whether an alkaline 
phosphatase (ALP) value above 2-fold indicates Chol predominance 
and low risk of acute liver failure/liver transplantation (ALF/OLT).
Patients (or Materials) and Methods: The study cohort encompasses 
all patients with idiosyncratic DILI submitted to the Spanish DILI 
Registry until 2012. Clinical and biochemical analyses were per-
formed using available information from 805 episodes in 771 patients 
at 3 different time points: DILI onset, peak of ALT, and peak of TBL.
Results: Thirty-one (4%) patients developed ALF/OLT. Sixty-five 
percent of the cases were HC (nR ≥ 5; nR calculated with AST or 
ALT (which ever being the highest) × ULN/ALP xULN). Of these, 28 
cases (5.5%) had ALF/OLT whereas only 2 (0.7%) in the chol/mixed 
group. Risk factors significantly associated to DILI-induced ALF/
OLT were HC injury, female sex, high AST/ALT ratio, and TBL. To 
ascertain the best criteria for predicting ALT/OLT cases, we compared 
all cases that fulfilled “Hy’s Law” definition according to ALT > 3 × 
ULN, R ≥ 5 (ALT × ULN/ALP x ULN) or nR ≥ 5 and TBL > 2 × ULN 
at various time points. nR criteria showed a better balance between 
sensitivity and specificity, mainly at onset as type of injury evolves 
into Chol damage. Of 282 who fulfilled these criteria, 27 had ALF/
OLT at onset, 25 of 280 at ALT peak, and 18 of 266 at TBL peak. 
The sensitivity ranged from 72% to 90% and specificity ranged from 
62% to 65%. Incidences of ALP ≥ 2 x ULN in patients who did or did 
not go on to develop ALF/OLT were similar and rarely ≥ 4 × ULN.
Conclusion: DILI patients with HC injury (nR ≥ 5) show a higher 
risk of ALF/OLT than Chol/Mix damage, with highest predictive 
value at DILI onset. Risk factors for ALF/OLT are HC injury, female 
sex, high AST/ALT ratio, and TBL. The definition of Hy´s law with 
nR at the first blood test available after presentation shows the major 
predictive value. Therefore, delayed presentation can complicate 
assessment of ALF risk. ALP levels > 2 × ULN do not exclude “true” 
Hy´s law cases and do not predict a lower risk of ALF/OLT.
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Introduction: Adverse drug reactions (ADR) are the fourth cause 
of death in Western Countries: people receive multiple medications, 
and resulting drug response may differ significantly from expected 
outcomes. Medigenia is a free health service that prevents ADR using 
the social security number (SSN).
Patients (or Materials) and Methods: Medigenia is a cloud-based 
smart city that collects patient’ s drug recruitment information from 
all the sources of exposure (pharmacy, general physician (GP), hos-
pital). The patient, freely registered to the service, is related through 
her/his SSN with the list of drugs administered.The element that con-
nects all health actors is a software solution that permits the creation 
of a unique electronic space where patient profiles are stored and 
updated. Medigenia supports GP in his decisions, providing him with 
an online pharmacologic profile of the patients, information about 
prescribed drugs/over the counter (OTC)/herbs, detailing dosage, 
number of packages and pills per package, prescription/purchase 
date, drug half-life, drug–drug interactions (DDIs), therapeutic index, 
and prescribing doctor. System also provides important information 
about patient’s global health status, inspecting comorbidity (Charlson 
age-adjusted Comorbidity Index), allergy, organ failure,and glucose6 
phosphate dehydrogenase deficit. Every complete profile permits to 
define, for each patient, a priori risk, expressed in percentage, which 
represents the probability of heading for ADR after taking a new 
drug. Range percentage identifies the risk among 3 cutoffs: low (from 
25% to 50%), moderate (from 50.1% to 75%) and high (> 75.1%).
Medigenia integrates a real-time alerting system that is automatically 
activated when pharmacologic risk, strictly related to a priori risk 
of the patient, overcomes those cutoffs: overtaken them, the doctor 
received a warning by e-mail for a timely therapy update.
